
FDA Grants Orphan Drug Designation to Ezurpimtrostat (GNS561) for Hepatocellular Carcinoma (HCC) Treatment
Genoscience Pharma today announces that its lead candidate, ezurpimtrostat (GNS561), a PPT-1 (Palmitoyl Protein Thioesterase-1) inhibitor, has been granted Orphan Drug Designation by the U.S. FDA for ...

FDA approves Apic Bio’s APB-102 for SOD1 Amyotrophic lateral sclerosis
Apic Bio, Inc. today announced that the US FDA had cleared its IND application for APB-102 to treat SOD1 Amyotrophic lateral sclerosis (ALS) – a common cause of familial ALS. APB-102 is a next-generat ...

PharmaEssentia Resubmits Ropeginterferon alfa-2b-njft Application to the US FDA to Treat Polycythemia Vera (PV)
PharmaEssentia USA Corporation, a global biopharmaceutical innovator, leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today announced th ...